Live feed08:30:00·14dNEWSReleasevia QuantisnowAs the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over AntibodiesByQuantisnow·Wall Street's wire, on your screen.NNVC· NanoViricides Inc.Health Care
